Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EPS (Weighted Average and Diluted) (2022 - 2024)

Historic EPS (Weighted Average and Diluted) for CervoMed (CRVO) over the last 7 years, with Q3 2024 value amounting to -$0.55.

  • CervoMed's EPS (Weighted Average and Diluted) rose 2142.86% to -$0.55 in Q3 2024 from the same period last year, while for Sep 2024 it was $2.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2022, which is 472.72% up from last year.
  • According to the latest figures from Q3 2024, CervoMed's EPS (Weighted Average and Diluted) is -$0.55, which was up 2142.86% from -$0.7 recorded in Q3 2023.
  • Over the past 5 years, CervoMed's EPS (Weighted Average and Diluted) peaked at $2.0 million during Q4 2022, and registered a low of -$1.7 during Q3 2022.
  • Over the past 3 years, CervoMed's median EPS (Weighted Average and Diluted) value was -$0.62 (recorded in 2023), while the average stood at $509724.1.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 5882.35% in 2023, then surged by 2142.86% in 2024.
  • CervoMed's EPS (Weighted Average and Diluted) (Quarter) stood at $2.0 million in 2022, then plummeted by 100.0% to -$0.7 in 2023, then rose by 21.43% to -$0.55 in 2024.
  • Its EPS (Weighted Average and Diluted) was -$0.55 in Q3 2024, compared to -$0.7 in Q3 2023 and $2.0 million in Q4 2022.